INTRODUCTION: The analysis of predictive factors of response may aid in predicting which patients with advanced renal cell carcinoma (RCC) would be good candidates for systemic treatments. MATERIALS AND METHODS: The expression of several biomarkers was retrospectively analyzed using immunohistochemistry (IHC), as well as 2 analytical variables in 135 patients with advanced RCC treated with cytokines (CK) and/or new targeted drugs (NTD). RESULTS: 67 patients were treated solely with NTD and 68 with CK (23 also received NTD). Univariate analysis: HIF1α did not correlate significantly with response to these drugs. Overexpression of CAIX was associated with more responses (%) to NTD (64.7 vs. 21.1; p = 0.004) and CK (22.6 vs. 0; p = 0.038). PTEN demonstrated predictive value of response to sunitinib (70.8 vs. 34.1; p = 0.005). p21 was associated with a lower response to sunitinib (35.9 vs. 65.4; p = 0.025). Thrombocytosis was not significantly associated with response to NTD, although it was with CK (0 vs. 20; p = 0.017). Neutrophilia correlated with a lower response to NTD (29.6 vs. 57.5; p = 0.045), although not with CK. Multivariate analysis: Overexpression of CAIX was an independent predictor of significantly higher response to NTD and CK; OR = 8.773 (p < 0.001). CONCLUSIONS: Our findings highlight the usefulness of CAIX in selecting patients with advanced RCC as candidates for systemic treatment. PTEN and p21 may be important in predicting response to sunitinib. Thrombocytosis and neutrophilia correlate well with response to CK and NTD, respectively.
INTRODUCTION: The analysis of predictive factors of response may aid in predicting which patients with advanced renal cell carcinoma (RCC) would be good candidates for systemic treatments. MATERIALS AND METHODS: The expression of several biomarkers was retrospectively analyzed using immunohistochemistry (IHC), as well as 2 analytical variables in 135 patients with advanced RCC treated with cytokines (CK) and/or new targeted drugs (NTD). RESULTS: 67 patients were treated solely with NTD and 68 with CK (23 also received NTD). Univariate analysis: HIF1α did not correlate significantly with response to these drugs. Overexpression of CAIX was associated with more responses (%) to NTD (64.7 vs. 21.1; p = 0.004) and CK (22.6 vs. 0; p = 0.038). PTEN demonstrated predictive value of response to sunitinib (70.8 vs. 34.1; p = 0.005). p21 was associated with a lower response to sunitinib (35.9 vs. 65.4; p = 0.025). Thrombocytosis was not significantly associated with response to NTD, although it was with CK (0 vs. 20; p = 0.017). Neutrophilia correlated with a lower response to NTD (29.6 vs. 57.5; p = 0.045), although not with CK. Multivariate analysis: Overexpression of CAIX was an independent predictor of significantly higher response to NTD and CK; OR = 8.773 (p < 0.001). CONCLUSIONS: Our findings highlight the usefulness of CAIX in selecting patients with advanced RCC as candidates for systemic treatment. PTEN and p21 may be important in predicting response to sunitinib. Thrombocytosis and neutrophilia correlate well with response to CK and NTD, respectively.
Authors: Bernard Escudier; Tim Eisen; Walter M Stadler; Cezary Szczylik; Stéphane Oudard; Michael Siebels; Sylvie Negrier; Christine Chevreau; Ewa Solska; Apurva A Desai; Frédéric Rolland; Tomasz Demkow; Thomas E Hutson; Martin Gore; Scott Freeman; Brian Schwartz; Minghua Shan; Ronit Simantov; Ronald M Bukowski Journal: N Engl J Med Date: 2007-01-11 Impact factor: 91.245
Authors: Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Olivier Rixe; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Sindy T Kim; Isan Chen; Paul W Bycott; Charles M Baum; Robert A Figlin Journal: N Engl J Med Date: 2007-01-11 Impact factor: 91.245
Authors: Ahmedin Jemal; Taylor Murray; Elizabeth Ward; Alicia Samuels; Ram C Tiwari; Asma Ghafoor; Eric J Feuer; Michael J Thun Journal: CA Cancer J Clin Date: 2005 Jan-Feb Impact factor: 508.702
Authors: Tarek M Mekhail; Rony M Abou-Jawde; Gabriel Boumerhi; Sareena Malhi; Laura Wood; Paul Elson; Ronald Bukowski Journal: J Clin Oncol Date: 2005-02-01 Impact factor: 44.544
Authors: Michael Atkins; Meredith Regan; David McDermott; James Mier; Eric Stanbridge; Amanda Youmans; Philip Febbo; Melissa Upton; Mirna Lechpammer; Sabina Signoretti Journal: Clin Cancer Res Date: 2005-05-15 Impact factor: 12.531
Authors: Jean-Jacques Patard; Patricia Fergelot; Pierre I Karakiewicz; Tobias Klatte; Quoc-Dien Trinh; Nathalie Rioux-Leclercq; Jonathan W Said; Arie S Belldegrun; Allan J Pantuck Journal: Int J Cancer Date: 2008-07-15 Impact factor: 7.396
Authors: Jonathan M Weiss; W Gregory Alvord; Octavio A Quiñones; Jimmy K Stauffer; Robert H Wiltrout Journal: Hum Immunol Date: 2014-05-04 Impact factor: 2.850
Authors: David J Stewart; Maria I Nunez; Carmen Behrens; Diane Liu; Yan Heather Lin; J Jack Lee; Jack Roth; John Heymach; Stephen G Swisher; Waun Ki Hong; Ignacio Ivan Wistuba Journal: J Thorac Oncol Date: 2014-05 Impact factor: 15.609
Authors: Saadia A Aziz; Joshua Sznol; Adebowale Adeniran; John W Colberg; Robert L Camp; Harriet M Kluger Journal: J Transl Med Date: 2013-01-14 Impact factor: 5.531
Authors: Michele Milella; Italia Falcone; Fabiana Conciatori; Ursula Cesta Incani; Anais Del Curatolo; Nicola Inzerilli; Carmen M A Nuzzo; Vanja Vaccaro; Sabrina Vari; Francesco Cognetti; Ludovica Ciuffreda Journal: Front Oncol Date: 2015-02-16 Impact factor: 6.244
Authors: Robert J Motzer; Thomas E Hutson; Gary R Hudes; Robert A Figlin; Jean-Francois Martini; Patricia A English; Xin Huang; Olga Valota; J Andrew Williams Journal: Cancer Chemother Pharmacol Date: 2014-08-07 Impact factor: 3.333
Authors: Frede Donskov; M Dror Michaelson; Igor Puzanov; Mellar P Davis; Georg A Bjarnason; Robert J Motzer; David Goldstein; Xun Lin; Darrel P Cohen; Robin Wiltshire; Brian I Rini Journal: Br J Cancer Date: 2015-10-22 Impact factor: 7.640